These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25758352)

  • 41. International veterinary bioequivalence guideline similarities and differences between Australia, Canada, Europe, Japan, New Zealand and the United States.
    Lainesse C
    AAPS J; 2012 Dec; 14(4):792-8. PubMed ID: 22864669
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs.
    Krishna R; Kesisoglou F
    Clin Pharmacol Ther; 2019 Feb; 105(2):298-300. PubMed ID: 30456848
    [No Abstract]   [Full Text] [Related]  

  • 43. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.
    Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B
    AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
    Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
    Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Establishing bioequivalence for inhaled drugs; weighing the evidence.
    Daley-Yates PT; Parkins DA
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.
    Sferrazza G; Siviero PD; Nicotera G; Turella P; Serafino A; Blandizzi C; Pierimarchi P
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):1007-1019. PubMed ID: 28656793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global harmonization of immediate-release solid oral drug product bioequivalence recommendations and the impact on generic drug development.
    Kotsybar J; Hakeem S; Zhang L; Jiang W
    Clin Transl Sci; 2023 Dec; 16(12):2756-2764. PubMed ID: 37904315
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action.
    Verbeeck RK; Musuamba FT
    J Pharm Pharm Sci; 2012; 15(3):376-88. PubMed ID: 23148877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro and in vivo equivalence testing of nanoparticulate intravenous formulations.
    Pathak SM; Ruby PK; Aggarwal D
    Drug Res (Stuttg); 2014 Apr; 64(4):169-76. PubMed ID: 24203084
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.
    Davit BM; Chen ML; Conner DP; Haidar SH; Kim S; Lee CH; Lionberger RA; Makhlouf FT; Nwakama PE; Patel DT; Schuirmann DJ; Yu LX
    AAPS J; 2012 Dec; 14(4):915-24. PubMed ID: 22972221
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bioequivalence studies: single vs multiple dose.
    Steinijans VW; Sauter R; Jonkman JH; Schulz HU; Stricker H; Blume H
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Considerations in establishing bioequivalence of inhaled compounds.
    Mayers I; Bhutani M
    Expert Opin Drug Deliv; 2018 Feb; 15(2):153-162. PubMed ID: 28918665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viewpoint: observations on scaled average bioequivalence.
    Patterson SD; Jones B
    Pharm Stat; 2012; 11(1):1-7. PubMed ID: 22162308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.
    Chen ML; Blume H; Beuerle G; Davit B; Mehta M; Potthast H; Schug B; Tsang YC; Wedemeyer RS; Weitschies W; Welink J
    Eur J Pharm Sci; 2018 Jan; 111():153-157. PubMed ID: 28964950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Trends in the quality evaluation of generic products and bioequivalence guidelines].
    Yomota C
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):1-12. PubMed ID: 23243982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioequivalence requirements in the European Union: critical discussion.
    García-Arieta A; Gordon J
    AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioequivalence and generic prescribing: an industrial view.
    Pidgen A
    J Pharm Pharmacol; 1996 Jan; 48(1):11-6. PubMed ID: 8722487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA mulls changes to bioequivalence standards.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.